This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bookman, M. A. Search for Related Content PubMed PubMed Citation Articles by Bookman, M. A.

Extending the Platinum-Free Interval in Recurrent Ovarian Cancer: The Role of Topotecan in Second-Line Chemotherapy

Medical Gynecologic Oncology, Medical Information Management, Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA

Correspondence: Michael A. Bookman, M.D., Medical Gynecologic Oncology, Medical Information Management, Department of Medical Oncology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, Pennsylvania, 19111 USA. Telephone: 215-728-2987; Fax: 215-728-3639; e-mail: ma_bookman{at}fccc.edu

Although the combination of platinum and paclitaxel offers effective chemotherapy for advanced ovarian cancer, the majority of women will eventually relapse with development of drug-resistant disease. Topotecan is the most extensively studied agent currently available for management of recurrent ovarian cancer and has been approved by the FDA for that particular indication. Early use of topotecan offers an effective and tolerable strategy that can prolong the platinum-free interval and optimize subsequent retreatment with platinum.

Key Words. Platinum-free interval (PFI) • Ovarian cancer • Topotecan • Relapsed or recurrent disease • Second-line chemotherapy

This article has been cited by other articles:

				J. Sehouli, D. Stengel, G. Oskay-Oezcelik, A. G. Zeimet, H. Sommer, P. Klare, M. Stauch, A. Paulenz, O. Camara, E. Keil, et al. Nonplatinum Topotecan Combinations Versus Topotecan Alone for Recurrent Ovarian Cancer: Results of a Phase III Study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group J. Clin. Oncol., July 1, 2008; 26(19): 3176 - 3182. [Abstract] [Full Text] [PDF]

				S. A. Cannistra Is There a "Best" Choice of Second-Line Agent in the Treatment of Recurrent, Potentially Platinum-Sensitive Ovarian Cancer? J. Clin. Oncol., March 1, 2002; 20(5): 1158 - 1160. [Full Text] [PDF]